Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals (ALNY) sees significant social media engagement surge following positive HELIOS-B study data and strong Amvuttra sales, despite some negative sentiment on X and regulatory concerns.

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics.
Alnylam Pharmaceuticals, Inc. uses the ticker $ALNY for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

• Alnylam Pharmaceuticals, Inc. (ALNY) market dominance near a 52-week low at [-------].
• Alnylam Pharmaceuticals, Inc. (ALNY) sentiment is up 34% from the previous week.
• Alnylam Pharmaceuticals, Inc. (ALNY) creators is up 23.42% from the previous week.
• Alnylam Pharmaceuticals, Inc. (ALNY) engagements is up 256.22% from the previous week.
• Alnylam Pharmaceuticals, Inc. (ALNY) mentions is up 34.23% from the previous week.
• Alnylam Pharmaceuticals, Inc. (ALNY) posts created is up 161.54% from the previous week.

Price: $340.60

Price 24-Hour Time-Series Raw Data
The stock price is experiencing volatility, with positive clinical trial data and strong sales being offset by regulatory concerns and negative social media sentiment, leading to a balanced outlook.

24-Hour: -0.01% 7-Day: 3.99% 30-Day: -5.2%

1-Year High: $491.20 on 2025-10-20
1-Year Low: $224.30 on 2025-04-08

AltRank: [---]

AltRank 24-Hour Time-Series Raw Data
Alnylam Pharmaceuticals, Inc. (ALNY) is currently AltRank #763 based on combined combined social and market metrics Daily Average: [---]
[--] Week: [---] [----]
[--] Month: [---] +27
[--] Months: [---] +387
[--] Year: [---] +166
1-Year High: [-----] on 2025-06-08
1-Year Low: [--] on 2025-03-22

Galaxy Score: [-----]

Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] +1
[--] Month: [--] [---]
[--] Months: [--] [---]
[--] Year: [--] [---]
1-Year High: [--] on 2026-01-01
1-Year Low: [--] on 2025-06-26

Engagements: [-----] (24h)

Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [-------] +256%
[--] Month: [-------] -41%
[--] Months: [---------] -26%
[--] Year: [---------] -22%
1-Year High: [-------] on 2025-03-21
1-Year Low: [---] on 2026-02-17

Engagements by network (24h): News: [---] Reddit: [--] X: [-----] YouTube: [--]

Mentions: [--] (24h)

Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [---]
[--] Week: [---] +34%
[--] Month: [---] +6.20%
[--] Months: [-----] -32%
[--] Year: [-----] -15%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-12-07

Mentions by network (24h): News: [--] Reddit: [--] X: [--] YouTube: [--]

Creators: [--] (24h)

Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Alnylam Pharmaceuticals, Inc. (ALNY) in the last [--] hours which is down 57% from [--] in the previous [--] hours Daily Average: [---]
[--] Week: [---] +23%
[--] Month: [---] +12%
[--] Months: [-----] -42%
[--] Year: [-----] +54%
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2025-12-07

The most influential creators that mention Alnylam Pharmaceuticals, Inc. in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@GeneInvesting	[--]	[------]	[--]	[---]
@RNAiAnalyst	[--]	[------]	[--]	[---]
@Andre_AGTC	[--]	[-----]	[--]	[---]
@Tickeron	[--]	[------]	[--]	[---]
@AnitaMc26910087	[--]	[---]	[--]	[--]
@Quantumup1	[--]	[-----]	[--]	[--]
@MarcJacksonLA	[--]	[-----]	[--]	[--]
@BuyTheUgly	[--]	[--]	[--]	[--]
@alnylampharmaceuticals	[--]	[-----]	[--]	[--]
@TTRAmyloid	[--]	[-----]	[--]	[--]

View More

Sentiment: 67%

Sentiment 24-Hour Time-Series Raw Data
Current Value: 67%
Daily Average: 67%
[--] Week: 67% +17%
[--] Month: 58% -11%
[--] Months: 58% -20%
[--] Year: 58% no change
1-Year High: 100% on 2025-07-29
1-Year Low: 26% on 2025-12-02

Most Supportive Themes:

• Positive Data from HELIOS-B Study: (35%) New data from the HELIOS-B Phase [--] study shows reduced gastrointestinal events in ATTR-CM patients treated with Vutrisiran, supporting its use as a first-line therapy.
• Amvuttra Sales and Revenue Guidance: (20%) Alnylam reported strong Amvuttra sales and increased its [----] revenue guidance, indicating positive financial performance.
• First Patient Dosed in ZENITH Trial: (15%) Alnylam announced the first patient has been dosed in the ZENITH Global Phase [--] cardiovascular outcomes trial of Zilebesiran, marking progress in its clinical pipeline.

Most Critical Themes:

• Negative Sentiment on X: (20%) A significant portion of posts on X express negative sentiment, with users raising concerns about the company.
• FDA Crackdown and Ad Pull: (10%) Alnylam has withdrawn TV advertisements following regulatory action on drug industry advertising, which may lead to concerns.

Social Dominance: 0.00418%

Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00418%
Daily Average: 0.025%
[--] Week: 0.00651% -0.0009899999999999996%
[--] Month: 0.015% -0.0075%
[--] Months: 0.015% -0.025%
[--] Year: 0.015% -0.018%
1-Year High: 0.065% on 2025-03-24
1-Year Low: 0.0055% on 2025-12-07

Market Dominance: 0.047%

Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.047%
Daily Average: 1%
1-Year High: 2.10% on 2025-12-02
1-Year Low: 0.047% on 2026-02-16

Market Cap: $41,694,064,011

Market Cap 24-Hour Time-Series Raw Data
Current Value: $41,694,064,011
Daily Average: $47,121,854,657
[--] Week: $41,696,716,474 -2.70%
[--] Month: $41,696,716,474 -12%
[--] Months: $41,696,716,474 -31%
[--] Year: $41,696,716,474 +26%
1-Year High: $64,388,633,748 on 2025-10-20
1-Year Low: $29,032,966,164 on 2025-04-08

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing